MétaCan
Menu
Back to cohort
Record W3106627685

Ketamine for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]

2020· review· en· W3106627685 on OpenAlexaboutno aff
Khai Tran, Suzanne McCormack

Bibliographic record

Venuenot available
Typereview
Languageen
FieldMedicine
TopicTreatment of Major Depression
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineKetamineChronic painNeuropathic painOpioidAnalgesicFibromyalgiaAnesthesiaPsychiatryInternal medicine
DOInot available

Abstract

fetched live from OpenAlex

In Canada, about one in five adults older than 18 years of age live with chronic pain. Pain can be sub-defined by three main biological mechanisms: 1) Nociceptive pain (from damage to body tissue, as in injury, disease or inflammation); 2) Neuropathic pain (from direct damage of the nervous system); and 3) Nociplastic pain (from a change in sensory neurons function). Chronic pain is associated with significant emotional distress, like anxiety, anger, frustration and depression, and is recognized by the World Health Organization as a disease by itself listed in the International Classification of Disease version 11. Treatment and management of chronic pain are complex and difficult, involving multiple interventions, including pharmacological and psychological interventions. Pharmacological interventions considered for chronic pain include nonopioid analgesics (e.g., nonsteroidal anti-inflammatory drugs, acetaminophen), antidepressants, antiepileptic drugs, other adjuvant medications (e.g., topical agents, cannabis and cannabinoids), opioid, and infusion therapies (e.g., ketamine, lidocaine).Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been approved and primarily used as an anesthetic induction agent in doses ranging between 1 and 4.5 mg/kg. As it also interacts with other receptors, ketamine has been explored for other indications such as depressive disorders, suicidal ideation, substance-use disorders, anxiety disorders, refractory status epilepticus, bronchial asthma exacerbations, and pain management. In hospital and emergency department, ketamine has been used for pain management of acute conditions such as burns, trauma, or post-operative pain. Recently, intravenous (IV) ketamine infusions has been increasingly used as a treatment option for acute pain as well as chronic non-cancer pain such as complex regional pain syndrome (CRPS), neuropathic pain, and other refractory chronic pain conditions. Despite potential opportunities of ketamine for numerous indications, the use of ketamine is known to be associated with psychotomimetic effects such as euphoria, dysphoria, psychomotor retardation, hallucinations, vivid dreams, and nightmares, as common side effects. Given the availability of ketamine of different formulations and its potential opportunities in pain management, there is a need to determine its benefits and risks in the treatment of chronic pain.The aim of this report is to review the evidence regarding the clinical effectiveness and cost-effectiveness of ketamine for treating chronic non-cancer pain in adults. This report also aims to review the evidence-based guidelines regarding the use of ketamine for chronic non-cancer pain.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.011
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.015
Threshold uncertainty score0.036

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.011
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.004
Bibliometrics0.0060.007
Science and technology studies0.0000.001
Scholarly communication0.0020.002
Open science0.0020.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0070.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.228
GPT teacher head0.530
Teacher spread0.302 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2020
Admission routes1
Has abstractyes

Explore more

Same topicTreatment of Major DepressionFrench-language works237,207